Rezolute, Inc. Common Stock (NV) (RZLT) Stock Price
RZLTStock
$4.62−36.01%52W
Market Cap$444.87M
P/E—
PEG Ratio—
Div yield—
Beta0.49
RZLT Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)16.05%
Price vs S&P 500 (4W)-7.45%
VGM Score54.39
RZLT Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q4 2025 | -$0.18 | -$0.22 | -22.22%(-$0.04) | |
| Q3 2025 | -$0.26 | -$0.18 | +31.21%(+$0.08) | |
| Q2 2025 | -$0.23 | -$0.26 | -10.64%(-$0.03) |
RZLT Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.13
4.13
4.19
4.19
Industry Peers — Pharmaceuticals(570)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
RZLTRezolute, Inc. Common Stock (NV) | — | — | C | $4.62 |
| LLYEli Lilly & Co. | D | B | C | $1174.61 |
| JNJJohnson & Johnson | D | C | B | $268.04 |
| ABBVABBVIE INC. | D | C | B | $255.48 |
| MRKMerck & Co., Inc. | D | C | B | $148.35 |
| NVSNovartis AG | C | C | C | $153.81 |
| AZNAstraZeneca PLC | C | B | C | $162.70 |
| NVONovo-Nordisk A/S | B | C | C | $45.61 |
| ABTAbbott Laboratories | C | C | C | $112.47 |
| PFEPfizer Inc. | C | D | B | $27.96 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $541.69 |
About Rezolute, Inc. Common Stock (NV)
Rezolute is a clinical-stage biopharmaceutical company developing therapies for rare metabolic diseases, including congenital hyperinsulinism, a rare endocrine disorder characterized by excessive insulin production and hypoglycemia. Its pipeline candidates aim to improve patient outcomes with reduced treatment burdens. Value creation depends on successful clinical development and regulatory approval.